News
New study of diabetes drug for COVID-19 raises eyebrows
May 1, 2020
Some question the safety of AstraZeneca’s just-launched DARE-19 study testing whether dapagliflozin will reduce adverse outcomes of COVID-19.
News
SGLT2 inhibitor ertugliflozin shows no CV death or renal benefit
April 29, 2020
Merck reports topline results from ertugliflozin’s FDA-mandated cardiovascular outcomes trial.
![1]()
News
Inflammatory markers may explain COVID-19, diabetes dynamic
April 15, 2020
Higher levels of markers may signal greater susceptibility to cytokine storm.
News
Dapagliflozin trial in CKD halted because of high efficacy
March 30, 2020
An independent data monitoring committee recommended stopping the trial.
News
Larger absolute rivaroxaban benefit in diabetes: COMPASS
March 29, 2020
The new vascular low dose of rivaroxaban has had a slow start, but these results may stimulate use in patients with diabetes and stable disease.
News
Keep calm: Under 25s with diabetes aren’t being hospitalized for COVID-19
March 26, 2020
But some are concerned that type 1 diabetes diagnoses are being delayed.
News
FDA advises stopping SGLT2 inhibitor treatment prior to surgery
March 18, 2020
The changes affect canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin, and were made because surgery may put patients taking SGLT2 inhibitors at a higher risk of ketoacidosis.
![1]()
News
Treating COVID-19 in patients with diabetes
March 17, 2020
Most health advisories about COVID-2019 mention diabetes as one of the high-risk categories for the disease.
News
COVID-19: Extra caution needed for patients with diabetes
March 17, 2020
Coexisting heart disease, kidney disease, advanced age, and frailty are likely to further increase the severity of disease.
News
MACE benefits with dapagliflozin improve with disease duration
March 4, 2020
Findings suggest treatment with the SGLT-2 inhibitor should be initiated early in some high-risk patients.
